Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial

BACKGROUND: Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear. METHODS: Eligible patients included those with advanced NSCLC with meas...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimura, Keiko, Uchino, Junji, Kimura, Hideharu, Hiranuma, Osamu, Chihara, Yusuke, Tanzawa, Shigeru, Takumi, Chieko, Kita, Toshiyuki, Inoue, Koji, Minato, Koichi, Takemoto, Shinnosuke, Nakao, Akira, Yoshimura, Kenichi, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243767/
https://www.ncbi.nlm.nih.gov/pubmed/37053467
http://dx.doi.org/10.1093/oncolo/oyad013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243767/
https://www.ncbi.nlm.nih.gov/pubmed/37053467
http://dx.doi.org/10.1093/oncolo/oyad013

Ejemplares similares